公开(公告)号：NO20064351L

公开(公告)日：2006-11-20

申请号：NO20064351

申请日：2006-09-26

Applicant: VERTEX PHARMA

Inventor： STUDLEY JOHN ,  CHARRIER JEAN-DAMIEN ,  MORTIMORE MICHAEL ,  DURRANT STEVEN ,  O'DONNELL MICHAEL ,  RUTHERFORD ALISTAIR ,  RAMAYA SHARN ,  TRUDEAU MARTIN ,  LOOKER ADAM

IPC: C07D207/16 ,  A61K31/439 ,  A61K38/04 ,  A61K38/06 ,  C07D209/52 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D417/06 ,  C07D417/12 ,  C07K5/02 ,  C07K5/04

Abstract: The present invention provides a compound of formula (I): wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.

公开(公告)号：CA2606780A1

公开(公告)日：2006-11-16

申请号：CA2606780

申请日：2006-05-09

Applicant: VERTEX PHARMA

Inventor： LOOKER ADAM ,  SNOONIAN JOHN R ,  NYCE PHILIP L ,  BLYTHE TODD A ,  ANSELL GRAHAM ,  JONES ANDREW D ,  LITTLER BENJAMIN

IPC: C07C275/42 ,  C07C271/34 ,  C07D307/16 ,  C07D413/12

Abstract: The present invention relates to processes for preparing biaryl ureas derivatives and analogs thereof. The invention also provides compounds useful as intermediates in the processes of the present invention. The process is useful for preparing compounds that inhibit IMPDH.

公开(公告)号：PL3717455T3

公开(公告)日：2025-03-24

申请号：PL18816468

申请日：2018-11-30

Applicant: VERTEX PHARMA

Inventor： LEMERCIER LEWANDOWSKI BERENICE ,  LEWIS ROBERT ,  LOOKER ADAM ,  MORGAN ADAM ,  ROEPER STEFANIE ,  RYAN MICHAEL ,  SOLSONA ROCABERT JUAN GABRIEL ,  WILDE NATHAN

IPC: C07D215/56 ,  C07B59/00 ,  C07C33/18 ,  C07C69/96

公开(公告)号：CO2021016594A2

公开(公告)日：2022-04-29

申请号：CO2021016594

申请日：2021-12-07

Applicant: VERTEX PHARMA

Inventor： BLIGH CAVAN MCKEON ,  BRODNEY MICHAEL AARON ,  GAGNON KEVIN JAMES ,  HOOD SARAH CAROL ,  LOOKER ADAM ,  MAXWELL JOHN PATRICK ,  MEDEK ALES ,  RODAY SETU ,  ROEPER STEFANIE ,  SAWANT RUPA ,  SHI YI ,  TANG QING ,  BANDARAGE UPUL KEERTHI ,  BOYD MICHAEL JOHN ,  DAMAGNEZ VERONIQUE ,  GIROUX SIMON ,  GREY JR RONALD LEE ,  HALL AMY BETH ,  HURLEY DENNIS JAMES ,  JOHNSON JR MAC ARTHUR ,  JONES PETER ,  KESAVAN SARATHY ,  NUHANT PHILIPPE MARCEL ,  SWETT REBECCA JANE ,  TAPLEY TIMOTHY LEWIS ,  XU JINWANG ,  COTTRELL KEVIN MICHAEL ,  SHRESTHA MUNA ,  BOUCHER DIANE ,  CLARK MICHAEL PHILIP ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  FLEMING GABRIELLE SIMONE ,  GARCIA BARRANTES PEDRO MANUEL ,  GIACOMETTI ROBERT DANIEL ,  GUIDO SAMANTHA ,  LAI MEI-HSIU ,  LIU SIYING ,  MAXWELL BRAD ,  OVERHOFF KIRK ALAN ,  RONKIN STEVEN M ,  SPOSATO MARISA ,  STAVROPOULOS KATHY ,  THOMSON STEPHEN ,  ZAKY MARIAM

IPC: C07D231/56 ,  A61K31/4162 ,  A61K31/429 ,  A61P1/16 ,  A61P11/00 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos.

公开(公告)号：CR20210608A

公开(公告)日：2022-02-11

申请号：CR20210608

申请日：2020-05-14

Applicant: VERTEX PHARMA

Inventor： BLIGH CAVAN MCKEON ,  GUIDO SAMANTHA ,  HOOD SARAH CAROL ,  THOMSON STEPHEN ,  BOYD MICHAEL JOHN ,  DAMAGNEZ VERONIQUE ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  KESAVAN SARATHY ,  MAXWELL JOHN PATRICK ,  OVERHOFF KIRK ALAN ,  STAVROPOULOS KATHY ,  XU JINWANG ,  CLARK MICHAEL PHILIP ,  GAGNON KEVIN JAMES ,  GIACOMETTI ROBERT DANIEL ,  GIROUX SIMON ,  LOOKER ADAM ,  MEDEK ALES ,  FLEMING GABRIELLE SIMONE ,  HURLEY DENNIS JAMES ,  RONKIN STEVEN M ,  SHRESTHA MUNA ,  JONES PETER ,  BOUCHER DIANE ,  BRODNEY MICHAEL AARON ,  GARCIA BARRANTES PEDRO MANUEL ,  NUHANT PHILIPPE MARCEL ,  HALL AMY BETH ,  RODAY SETU ,  SAWANT RUPA ,  SPOSATO MARISA ,  BANDARAGE UPUL KEERTHI ,  JOHNSON JR MAC ARTHUR ,  LAI MEI-HSIU ,  MAXWELL BRAD ,  SWETT REBECCA JANE ,  ZAKY MARIAM ,  COTTRELL KEVIN MICHAEL ,  GREY JR RONALD LEE ,  LIU SIYING ,  ROEPER STEFANIE ,  TANG QING ,  TAPLEY TIMOTHY LEWIS ,  SHI YI

IPC: A61K31/429 ,  A61K31/4162 ,  A61P1/16 ,  A61P11/00 ,  C07D231/56 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos

公开(公告)号：CA3140039A1

公开(公告)日：2020-12-10

申请号：CA3140039

申请日：2020-05-14

Applicant: VERTEX PHARMA

Inventor： BANDARAGE UPUL KEERTHI ,  BLIGH CAVAN MCKEON ,  BOUCHER DIANE ,  BOYD MICHAEL JOHN ,  BRODNEY MICHAEL AARON ,  CLARK MICHAEL PHILIP ,  DAMAGNEZ VERONIQUE ,  FANNING LEV TYLER DEWEY ,  FIMOGNARI ROBERT FRANCIS ,  FLEMING GABRIELLE SIMONE ,  GAGNON KEVIN JAMES ,  GARCIA BARRANTES PEDRO MANUEL ,  GIACOMETTI ROBERT DANIEL ,  GIROUX SIMON ,  GREY JR RONALD LEE ,  GUIDO SAMANTHA ,  HALL AMY BETH ,  HOOD SARAH CAROL ,  HURLEY DENNIS JAMES ,  JOHNSON JR ,  JONES PETER ,  KESAVAN SARATHY ,  LAI MEI-HSIU ,  LIU SIYING ,  LOOKER ADAM ,  MAXWELL BRAD ,  MAXWELL JOHN PATRICK ,  MEDEK ALES ,  NUHANT PHILIPPE MARCEL ,  OVERHOFF KIRK ALAN ,  RODAY SETU ,  ROEPER STEFANIE ,  RONKIN STEVEN M ,  SAWANT RUPA ,  SHI YI ,  SHRESTHA MUNA ,  SPOSATO MARISA ,  STAVROPOULOS KATHY ,  SWETT REBECCA JANE ,  TANG QING ,  TAPLEY TIMOTHY LEWIS ,  THOMSON STEPHEN ,  XU JINWANG ,  ZAKY MARIAM ,  COTTRELL KEVIN MICHAEL

IPC: A61K31/4162 ,  A61K31/429 ,  A61P1/16 ,  A61P11/00 ,  C07D231/56 ,  C07D487/04 ,  C07D498/18 ,  C07D513/04

Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

公开(公告)号：CA2839937C

公开(公告)日：2020-11-03

申请号：CA2839937

申请日：2012-07-03

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  JUNG YOUNG CHUN ,  MAGDZIAK DEREK ,  LOOKER ADAM ,  KLINE BILLIE J ,  JURCIK VACLAV ,  DOMINGUEZ OLMO BEATRIZ

IPC: C07D471/04

Abstract: The present invention relates to processes and intermediate for the preparation of compounds of Formula l (see formula I) useful as inhibitors of Janus Kinases (JAK).

公开(公告)号：BR112014000115A2

公开(公告)日：2016-10-04

申请号：BR112014000115

申请日：2012-07-03

Applicant: VERTEX PHARMA

Inventor： LOOKER ADAM ,  OLMO BEATRIZ DOMINGUEZ ,  KLINE BILLIE J ,  MAGDZIAK DEREK ,  TANOURY GERALD J ,  JURCÍK VÁCLAV ,  JUNG YOUNG CHUN

IPC: C07D471/04

公开(公告)号：NZ619699A

公开(公告)日：2016-03-31

申请号：NZ61969912

申请日：2012-07-03

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  JUNG YOUNG CHUN ,  MAGDZIAK DEREK ,  LOOKER ADAM ,  KLINE BILLIE J ,  JURČÍK VÁCLAV ,  DOMINGUEZ OLMO BEATRIZ

IPC: C07D471/04 ,  A61K31/437 ,  C07D239/42 ,  C07F5/02 ,  C07F5/04

Abstract: Disclosed herein is a process for preparing an azaindole compound of Formula I, wherein the substituents are as defined in the specification. The process comprises reacting intermediates in water, organic solvents, a base, and a transition metal catalyst, wherein the organic solvents are selected from the group consisting of acetonitrile, toluene, N,N-dimethylformamide, N,N-dimethylacetamide, acetone, methyl tert-butyl ether, methanol, propanol, isopropanol, butanol, and tert-butanol. In a particular embodiment, the process produces compounds of Formula Ia [(R)-2-(2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide] and Ib [2-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)-2-methy-N-(2,2,2-trifluoroethy)propanamideand (Ib)]. The compounds of Formula I are useful as inhibitors of Janus kinases (JAK).

公开(公告)号：AU2012335714A1

公开(公告)日：2014-05-22

申请号：AU2012335714

申请日：2012-11-08

Applicant: VERTEX PHARMA

Inventor： LOOKER ADAM ,  LITTLER BENJAMIN JOSEPH ,  CHOUDHURY ANUSUYA ,  HARRISON CRISTIAN L ,  VELURI RAVIKANTH ,  RYAN MICHAEL P ,  JIANG LICONG ,  LUSS-LUSIS EDUARD

IPC: C07D405/12 ,  A61K31/405 ,  A61K31/553 ,  A61P1/00 ,  A61P3/00 ,  A61P11/00 ,  A61P25/00 ,  A61P27/00 ,  A61P35/00 ,  C07D405/14 ,  C07D498/04

Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.